Peptide Therapy for Men: The GH Axis, Testosterone, and Who It Fits

Peptide therapy for men centers on the GH axis and how it moves alongside testosterone. The peptides used most in men's clinics are GHRH analogs (sermorelin, CJC-1295, tesamorelin) and one growth hormone releasing peptide (ipamorelin), and each stimulates the pituitary to release a man's own growth hormone rather than injecting it. Sermorelin is a synthetic fragment of growth hormone-releasing hormone that binds pituitary receptors to raise GH output ^[1]. What follows is which peptides matter for men, how they interact with testosterone, and who is actually a candidate. This is the men's read on peptide therapy; the same axis behaves differently in women.

The GH-axis peptides men actually use

Four peptides cover most men's protocols, and they differ mainly in half-life and how the GH pulse is shaped. Sermorelin and the older GHRH fragment act quickly and clear quickly, which keeps release pulsatile and close to the body's own rhythm. CJC-1295 is a GHRH analog engineered for a longer half-life ^[4], and a single dose raises GH and IGF-1 for days in healthy adults ^[5]. The extension comes from a substitution that slows metabolic clearance of the GHRH fragment ^[3].

Ipamorelin works through a different receptor. It is a growth hormone releasing peptide, not a GHRH analog, and it triggers GH release selectively without the cortisol or prolactin rise seen with older secretagogues ^[6]. That selectivity is why it is the releasing peptide most often paired with a GHRH analog in a stack. The two act on separate pathways, so combining them produces a larger GH pulse than either alone.

How testosterone changes the picture

The GH axis and the testosterone axis are linked, which is why men's peptide programs read them together. Testosterone administration raises IGF-1 in men on its own ^[9], so a man with low testosterone often has a blunted GH-axis response that improves once androgens are corrected. In older men, testosterone and growth hormone given together improved lean mass and muscle performance more than either alone ^[10].

The interaction runs in both directions. Raising testosterone in older men with low levels increased GH secretion, and the effect tracked with the rise in estradiol from aromatization rather than testosterone itself ^[11]. The practical point for a man weighing peptide therapy is direct. If testosterone is low, treating the GH axis alone leaves part of the problem unaddressed. A program that measures only IGF-1 and ignores the androgen panel is working with half the data.

Who is a candidate

The candidate is a man over 30 with symptomatic GH-axis decline and a baseline IGF-1 in the low or low-normal range, not a young man with normal labs chasing performance. Symptoms that line up with the labs matter more than any single number: reduced lean mass, more visceral fat, poor slow-wave sleep, slow recovery, and low drive. A full androgen panel belongs in the same intake, because low testosterone changes both the diagnosis and the protocol.

• Men over 30 with low or low-normal IGF-1 and symptoms that match
• Men with low testosterone alongside GH-axis symptoms, where both axes are assessed
• Not for men with active malignancy or a pituitary tumor
• Not for men subject to anti-doping testing. GHRH analogs and releasing factors are on the WADA prohibited list ^[12]

Stacking, and where it goes wrong

The most common men's stack pairs a GHRH analog with ipamorelin, because the two hit different receptors and produce a larger, cleaner GH pulse than either alone ^[6]. That is a defensible combination once a single agent is working against a baseline. Adding a second peptide before the first has been evaluated at 90 days is guessing, not titration.

• Start with one GHRH analog and a baseline IGF-1, then retest at 90 days before adding anything
• Ipamorelin is the sensible second agent because it does not raise cortisol or prolactin ^[6]
• Tesamorelin is the choice when visceral fat is the main target, given its trial evidence for reducing abdominal fat ^[7]
• More peptides is not more benefit. Each addition should answer a specific gap the labs show

Safety and the honest limits

These peptides are compounded, which means they are not FDA-approved and their quality depends on the pharmacy. A 503B outsourcing facility is held to current good manufacturing practice standards; a 503A pharmacy is not ^[13]. Ask which fills your prescription and whether a Certificate of Analysis is available for your lot. Cost tracks the pharmacy and the labs more than the peptide, as peptide therapy cost lays out.

The evidence base in men is real but narrow. GHRH-analog studies in older adults show IGF-1 elevation and modest lean-mass gains ^[2], and tesamorelin has the strongest data for visceral fat ^[8]. None of this is a substitute for training and protein, and none of it is approved for anti-aging use.

Bottom line for men

Peptide therapy for men is GH-axis treatment that only reads correctly against testosterone. The right first step is not a peptide, it is two lab draws: a baseline IGF-1 and a full androgen panel. A program built from those numbers, prescribed by a physician who treats both axes, is the version of this that works.

SermorelinOnline Editorial TeamEditorial, SermorelinOnline.com

This site receives advertising fees from providers listed, which may influence ranking order. Fees do not influence review scores, which are assigned independently based on clinical and operational criteria.